Latest Breaking News On - Healthcare royalty partners - Page 8 : comparemela.com

Ardelyx, Inc (ARDX) Q3 2022 Earnings Call Transcript

Ardelyx, Inc. (NASDAQ:NASDAQ:ARDX) Q3 2022 Earnings Conference Call November 3, 2022 16:30 ET Company Participants Kimia Keshtbod - Investor Relations Justin Renz - Chief Financial Officer.

United statesLaura chicoMatt kaplanChris howertonPeter steinDavid rosenbaumMike raabJustin renzJoseph thomeLaura williamsKimia keshtbodSusan rodriguezYigal nochomovitzCompany participantsRenal drug advisory committeeLadenburg thalmann

Albireo Pharma Stock: Assessing The Sagard Deal (NASDAQ:ALBO)

Albireo Pharma is expanding Bylvay label for two other rare liver conditions, biliary atresia and Alagille syndrome. Read more about ALBO stock here.

United statesUnited kingdomMecklenburg vorpommernPhillip fisher warren buffettRon cooperAlbireo pharma incWarren buffettIntegrated biosci investingAlbireo pharmaHercules capitalHealthcare royalty partnersSagard healthcareFull therapeutic innovation

EU Expands Marketing Authorization for Rhythm s Imcivree to Treat Obesity and Control of Hunger in BBS

EU Expands Marketing Authorization for Rhythm s Imcivree to Treat Obesity and Control of Hunger in BBS
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPhilip bealesDavid meekerUniversity college londonEuropean commissionDrug administrationHealth technology assessmentEuropean unionHealth canadaInstitute of child healthRhythm pharmaceutical imcivreeOrmond street instituteRevenue interest financing agreementHealthcare royalty partnersHealthcare royalty

Rhythm Pharmaceuticals (RYTM) Announces IMCIVREE Granted Marketing Authorization by EC for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals (RYTM) Announces IMCIVREE Granted Marketing Authorization by EC for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomPhilip bealesDavid meekerUniversity college londonEuropean commissionDrug administrationHealth technology assessmentRhythm pharmaceuticals incEuropean unionHealth canadaInstitute of child healthRevenue interest agreementPriority reviewOrmond street instituteRevenue interest financing agreementHealthcare royalty partners

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide)

Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) EC authorization for BBS makes Rhythm eligible to receive second.

United statesUnited kingdomAdam daleyHannah deresiewiczPhilip bealesDavid meekerDavid connollyUniversity college londonStern investor relations incHealth technology assessmentUnited kingdom medicines healthcare products regulatory agencyEuropean unionDrug administrationEuropean commissionRhythm pharmaceuticalsExchange commission